Molika Ashford

The authors of a commentary said they view recent study results as informative, though limited, regarding the test's performance in prostate cancer.

Investigators are trialing methods to boost sensitivity for certain cancers, and assessing measures of how tests may impact clinical care in certain screening subpopulations.

Sophia sponsored a meeting gathering early adopters, pharma partners, and others to discuss the recently launched MSK-ACCESS, and soon-to-launch MSK-IMPACT kits.

Biotheranostics' CancerType ID can predict tumor origins for the majority of CUP patients, with reflex biomarker testing finding those eligible for targeted treatment.

The company is seeing its CYP2C19 test adopted broadly as it prepares to submit a new application to the FDA for an assay targeting neurodegenerative disease.

Guardant reached a major milestone in Q2 with the FDA approval of its Guardant Shield liquid biopsy colon cancer screening test.

The company increased its core customer base compared to the same period of 2023 and cited positive signs for its newest platform expansions.

The company said it screened more that 1 million people for colorectal cancer during the quarter, and also tested a record number with its Oncotype DX breast cancer test.

The company is gearing up to launch a new rapid NGS test for acute myeloid leukemia and a liquid biopsy comprehensive genomic profiling assay.

Neurologists treating patients who present with a small stroke or transient ischemic attack are now able to get PGx results to inform their prescription of Plavix within 24 hours.